Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | EVP, CFO and Treasurer | March 07, 2026 | March 09, 2026 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Executive Vice-President & CFO | February 19, 2021 | February 23, 2021 |
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | EVP & Chief Financial Officer | March 02, 2020 | March 04, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 07, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,599 |
Ending reported balance
After 2026-03-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-07 · Exercise / conversion · Acquired 12,223 · Balance 136,503 Row 2 · 2026-03-07 · Tax withholding · Disposed 5,904 · Balance 130,599 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2033-03-07 | Direct | 0 |
Reported balance
After 2026-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-07 · Exercise / conversion · Disposed 12,223 · Balance 0 F2: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F2: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date.
SUPERNUS PHARMACEUTICALS, INC.
Report date February 19, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.61 · Expires 2031-02-19 | Direct | 15,000 |
Reported balance
After 2021-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-19 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in four equal annual installments beginning on February 19, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal annual installments beginning on February 19, 2022.
Vanda Pharmaceuticals Inc.
Report date March 02, 2020 · Filed March 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 186,869 |
Ending reported balance
After 2020-03-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-02 · Sale · Disposed 12,968 · Balance 192,758 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.10 to $10.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Row 2 · 2020-03-03 · Sale · Disposed 5,889 · Balance 186,869 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.0001, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.10 to $10.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.0001, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2026 Filed Mar 9, 2026 22:13 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 12,223 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-025369 · tm268290-6_4seq1.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,223 shares Expires 2033-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2026 Filed Mar 9, 2026 22:13 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 5,904 | $9.98 | $58,921.92 |
DisclosureSEC source: 0001104659-26-025369 · tm268290-6_4seq1.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,599 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 07, 2026 Filed Mar 9, 2026 22:13 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 12,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-025369 · tm268290-6_4seq1.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 43,167 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023731 · tm268076-4_4seq1.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,333 Underlying: Common Stock · 43,167 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 20,850 | $9.49 | $197,866.50 |
DisclosureSEC source: 0001104659-26-023731 · tm268076-4_4seq1.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,280 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 43,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023731 · tm268076-4_4seq1.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:35 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantNon-statutory Stock Option NQ · Derivative | 194,000 | $9.09 Strike: $9.09 | $1,763,460.00 |
DisclosureSEC source: 0001104659-26-023072 · tm267953-3_4seq1.xml · derivative · entry 5 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,000 Underlying: Common Stock · 194,000 shares Expires 2036-03-03 F4 · derivative.exercise_date: One-quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:35 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 129,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023072 · tm267953-3_4seq1.xml · derivative · entry 4 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,500 Underlying: Common Stock · 129,500 shares Expires 2036-03-03 F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 2, 2026, in each case subject to continued employment through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 9, 2026 22:12 UTC Amendment | NOVAVAX INC NVAX · Entity 4632 | GrantNon-statutory Stock Option NQ · Derivative | 194,000 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001104659-26-025368 · tm268290-5_4seq1.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,000 Underlying: Common Stock · 194,000 shares Expires 2036-03-03 F1 · derivative.exercise_price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F1 · price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F2 · derivative.exercise_date: One-quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:35 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerRestricted Stock Units · Derivative | 58,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023072 · tm267953-3_4seq1.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,666 Underlying: Common Stock · 58,666 shares Expires 2034-03-01 F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:35 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 28,366 | $10.14 | $287,631.24 |
DisclosureSEC source: 0001104659-26-023072 · tm267953-3_4seq1.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,963 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:35 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 58,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023072 · tm267953-3_4seq1.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:33 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 12,223 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000332 · primary_01.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,223 Underlying: Common Stock · 12,223 shares Expires 2033-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:33 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 5,904 | $8.34 | $49,239.36 |
DisclosureSEC source: 0001593968-25-000332 · primary_01.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,251 Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:33 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 12,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000332 · primary_01.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Restricted Stock Units RSU · Derivative | 129,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000302 · primary_01.xml · derivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,500 Underlying: Common Stock · 129,500 shares Expires 2035-03-03 F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Non-statutory Stock Option NQ · Derivative | 194,500 | $7.87 Strike: $7.87 | $1,530,715.00 |
DisclosureSEC source: 0001593968-25-000302 · primary_01.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,500 Underlying: Common Stock · 194,500 shares Expires 2035-03-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 58,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000287 · primary_01.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,333 Underlying: Common Stock · 58,667 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 28,337 | $8.33 | $236,047.21 |
DisclosureSEC source: 0001593968-25-000287 · primary_01.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,932 Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:43 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 58,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000287 · primary_01.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:41 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000029 · primary_01.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2033-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vest with respect to one-half (1/2) of the RSUs on each of the first two (2) anniversaries of the grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:41 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 16,906 | $8.04 | $135,924.24 |
DisclosureSEC source: 0001593968-25-000029 · primary_01.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,602 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:41 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000029 · primary_01.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 2,367 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-001088 · primary_01.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,367 shares Expires 2031-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,223 | $12.96 | $15,850.08 |
DisclosureSEC source: 0001593968-24-001088 · primary_01.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,429 Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 2,367 | $12.96 | $30,676.32 |
DisclosureSEC source: 0001593968-24-001088 · primary_01.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033621 · tm248710-3_4seq1.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,608 Underlying: Common Stock · 4,608 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,226 | $5.45 | $12,131.70 |
DisclosureSEC source: 0001104659-24-033621 · tm248710-3_4seq1.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,285 Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:46 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,608 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-033621 · tm248710-3_4seq1.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:39 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 12,224 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033163 · tm248549-1_4seq1.xml · derivative · entry 4 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,446 Underlying: Common Stock · 12,224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:39 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 5,905 | $5.61 | $33,127.05 |
DisclosureSEC source: 0001104659-24-033163 · tm248549-1_4seq1.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,903 Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:39 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 12,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-033163 · tm248549-1_4seq1.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 01, 2024 Filed Mar 26, 2024 23:01 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 176,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-039164 · tm249879-4_4seq1.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| September 12, 2023 Filed Mar 12, 2024 01:39 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033163 · tm248549-1_4seq1.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest in full as of December 31, 2024, subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest in full as of December 31, 2024, subject to continued employment through such vesting date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 2,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046569 · doc4.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,367 Underlying: Common Stock · 2,366 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 16, 2021 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 16, 2021 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,143 | $7.13 | $8,149.59 |
DisclosureSEC source: 0001209191-23-046569 · doc4.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,584 Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 2,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046569 · doc4.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:19 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018550 · doc4.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 4,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:19 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,471 | $6.52 | $16,110.92 |
DisclosureSEC source: 0001209191-23-018550 · doc4.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:19 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,609 | $6.52 | $30,050.68 |
DisclosureSEC source: 0001209191-23-018550 · doc4.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 36,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017584 · doc4.xml · derivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,670 Underlying: Common Stock · 36,670 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:01 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 42,350 | $0.00 Strike: $6.97 | $0.00 |
DisclosureSEC source: 0001209191-23-017584 · doc4.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,350 Underlying: Common Stock · 42,350 shares Expires 2033-03-07 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 7, 2023 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 2,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046687 · doc4.xml · derivative · entry 3 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,733 Underlying: Common Stock · 2,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 16, 2021 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 16, 2021 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,144 | $42.88 | $49,054.72 |
DisclosureSEC source: 0001209191-22-046687 · doc4.xml · nonDerivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223 Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 21:02 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 2,367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046687 · doc4.xml · nonDerivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:48 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 13,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-018659 · doc4.xml · derivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,825 Underlying: Common Stock · 13,825 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:48 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 20,737 | $0.00 Strike: $77.77 | $0.00 |
DisclosureSEC source: 0001209191-22-018659 · doc4.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,737 Underlying: Common Stock · 20,737 shares Expires 2032-03-10 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 10, 2022 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 14,200 | $0.00 Strike: $229.31 | $0.00 |
DisclosureSEC source: 0001209191-21-052263 · doc4.xml · derivative · entry 2 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Common Stock · 14,200 shares Expires 2031-08-16 F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:16 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 7,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052263 · doc4.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 Underlying: Common Stock · 7,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the August 16, 2021 grant date (the "Grant Date"), subject to continued employment through each such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the August 16, 2021 grant date (the "Grant Date"), subject to continued employment through each such vesting date. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:55 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026940 · tm217706d11_4seq1.xml · derivative · entry 1 Kelly James Patrick · CIK 0001506314 · Executive Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-02-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.